Partnerships Link Firms, Nonprofits | Chemical & Engineering News
Volume 85 Issue 46 | p. 25 | Concentrates
Issue Date: November 12, 2007

Partnerships Link Firms, Nonprofits

Department: Business

The ALS Association has awarded Cambria Biosciences a $3.5 million contract to develop drugs blocking a mutant protein that, when misfolded, aggregates in the motor neurons of people with amyotrophic lateral sclerosis. The grant expands an earlier relationship between the nonprofit and the biotech firm, which received funding to develop neuroprotective compounds. Meanwhile, the nonprofit Drugs for Neglected Diseases initiative and the drug discovery and development company Scynexis have established a five-year partnership to advance molecules against parasites carrying human African trypanosomiasis, a disease that is plaguing sub-Saharan Africa. The $17 million collaboration also includes partners at Genzyme and Pace University.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment